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Transition from an M1 to a mixed
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amyloid deposition in APP/PS1 transgenic mice
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Abstract
Background: The polarization to different neuroinflammatory phenotypes has been described in early Alzheimer’s
disease, yet the impact of these phenotypes on amyloid-beta (Aβ) pathology remains unknown. Short-term studies
show that induction of an M1 neuroinflammatory phenotype reduces Aβ, but long-term studies have not been
performed that track the neuroinflammatory phenotype.
Methods: Wild-type and APP/PS1 transgenic mice aged 3 to 4 months received a bilateral intracranial injection of
adeno-associated viral (AAV) vectors expressing IFNγ or green fluorescent protein in the frontal cortex and hippocampus.
Mice were sacrificed 4 or 6 months post-injection. ELISA measurements were used for IFNγ protein levels and biochemical
levels of Aβ. The neuroinflammatory phenotype was determined through quantitative PCR. Microglia, astrocytes, and Aβ
levels were assessed with immunohistochemistry.
Results: AAV expressing IFNγ induced an M1 neuroinflammatory phenotype at 4 months and a mixed phenotype along
with an increase in Aβ at 6 months. Microglial staining was increased at 6 months and astrocyte staining was decreased
at 4 and 6 months in mice receiving AAV expressing IFNγ.
Conclusions: Expression of IFNγ through AAV successfully induced an M1 phenotype at 4 months that transitioned to a
mixed phenotype by 6 months. This transition also appeared with an increase in amyloid burden suggesting that a
mixed phenotype, or enhanced expression of M2a and M2c markers, could contribute to increasing amyloid burden and
disease progression.
Keywords: Inflammation, Alzheimer’s disease, Microglia, Beta-amyloid

Background
First described by Alois Alzheimer in 1907, Alzheimer’s
disease (AD) is a progressive, neurodegenerative disease
characterized pathologically by the presence of amyloid
plaques formed by amyloid-beta (Aβ) peptide aggregates
and neurofibrillary tangles composed of hyperphosphorylated and aggregated tau protein [1]. Alois Alzheimer also
described inflammation in the form of microglia surrounding amyloid plaques. Numerous studies have shown
that microglial activation results from a reaction to Aβ in
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AD [2-5]. The overall role of neuroinflammation in AD
remains relatively unknown.
Peripheral macrophages have been extensively characterized and shown to have distinct phenotypes dependent
on their stimuli. The M1 phenotype, or classical activation, is associated with defense and attack and induces the
release of pro-inflammatory cytokines such as IL-1β,
TNFα, IL-12 and IL-6 [6,7]. The M2 phenotypes are
termed alternative activation and include the M2a, M2b
and M2c states. The M2a phenotype is characterized by
wound healing and high levels of arginase 1 (ARG1) and
the chitinase-like protein YM1 [8]. The M2b phenotype is
a combination of an M1 and M2a state and is associated
with high levels of CD86 and the Fc gamma receptors 1
and 3 (FcγR1 and FcγR3) [8]. Finally, the M2c phenotype
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is a deactivation state accompanied by high levels of transforming growth factor beta and sphingosine kinase 1 [6,9].
It has more recently been shown that microglia are also
capable of expressing most, if not all, of these inflammatory mediators under the correct conditions.
The interferon family of cytokines has been shown to
be increased in human AD tissue and in the APP/PS1
mouse model, and IFNγ is the main stimulant for microglia to produce an M1 phenotype by binding its receptor,
increasing STAT1α, and increasing transcription of several M1 cytokine genes [10,11]. Some studies have used
IFNγ to induce an M1 phenotype, with one study showing that classical activation of microglia produces a
decrease and another reporting an increase in amyloid
burden [12,13]. Other studies have shown that inducing
an M1 neuroinflammatory phenotype by introducing
TNFα, IL-1β, or lipopolysaccharide (LPS) into the brain
lowers amyloid burden [14-17]. However, these studies
do not measure or track the different neuroinflammatory
phenotypes along with the changes in amyloid burden
over long periods of time. Additionally, engaging the immune system in the brain using anti-Aβ immunotherapy
has been shown to be extremely efficacious in lowering
amyloid load [18,19].
In order to better understand the long-term effects of
an M1 neuroinflammatory phenotype we bilaterally
injected an adeno-associated viral (AAV) vector expressing IFNγ into the frontal cortex and hippocampus of wildtype and APP/PS1 mice to induce an M1 phenotype and
determine the effects on Aβ levels at 4 and 6 months after
injection. We found that IFNγ induced an M1 phenotype
at 4 months but transitioned to include an M2 phenotype
by 6 months. The transition from an M1 to a mixed
phenotype did not ameliorate Aβ levels at 6 months.
Instead, Aβ levels were significantly higher, suggesting that
a mixed phenotype could accelerate the disease process.

Methods
Animals

Female and male wild-type (WT) and APP/PS1 transgenic
mice (C57BL6 mice carrying human APPSwe and PS1dE9 mutations) [20] were bred in house and aged for 3 to
4 months. Mice were randomly placed into one of eight
groups based on AAV serotype 8 (AAV-8) injection, genotype and survival. Fifteen WT mice were assigned to receive either AAV-8 expressing green fluorescent protein
(GFP) (GFP-AAV) for 4 months (n = 2 females, 1 male) or
6 months (n = 3 females, 3 males), or AAV-8 expressing
IFNγ (IFNγ-AAV) for 4 months (n = 2 females, 1 male) or
6 months (n = 2 females, 1 male). Twenty APP/PS1 mice
were assigned to receive either GFP-AAV for 4 months
(n = 2 females, 2 males) or 6 months (n = 4 females,
4 males) or IFNγ-AAV for 4 months (n = 2 females,
1 male) or 6 months (n = 2 females, 3 males). This study
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was approved by the University of Kentucky Institutional
Animal Care and Use Committee and conformed to the
National Institutes of Health Guide for the Care and Use
of Animals in Research.
Adeno-associated virus preparation

The vector for preparing recombinant AAV was constructed by ligating the 1349 bp EcoRI/SalI fragment carrying the IRES-GFP from pSMPUW-IRES-GFP (Cell Biolabs,
San Diego, CA, USA) into EcoRI/SalI-digested pZac2.1
(gift of Dr Paul Murphy, University of Kentucky) to create
ViCo1.28. The IFNγ insert was prepared by PCR amplification of cDNA clones obtained from Open Biosystems
(GE Healthcare, Dharmacon RNAi and gene expression,
Piscataway, NJ, USA). The IFNγ PCR primer sequence
used was CCCGCTAGCTCTGAGACAATGACCACCG
CGGACCCCGAATCAGCAGCGA. The Open Biosystems Catalogue number for the sequence is MMM101399829104. The clone ID is 8733812 and the accession is
BC119063. The primers introduced an NheI site at the
5’-end and a SacII site at the 3’-end of the IFNγ gene to
facilitate cloning into the corresponding sites in ViCo1.28.
The fidelity of each clone was confirmed by DNA
sequence analysis.
AAV8 coat protein-pseudotyped AAV2 viruses were
prepared by co-transfecting 10 T225 culture flasks of
293LTV cells (Cell Biolabs) with 250 μg pAAV2/8 (obtained from the University of Pennsylvania Viral Core),
500 μg pAdΔF6 (gift of Dr Paul Murphy) and, individually,
250 μg of each cytokine clone using 5 mg polyethyleneimine to enhance DNA uptake. After 3 days, the cells were
harvested, washed, suspended in 13 ml 150 mM NaCl,
50 mM Tris · Cl pH 8.4, 0.5% deoxycholate and 50 U/ml
of benzonase and incubated at 37°C for 30 minutes. An
additional 2.8 ml 5 M NaCl was added and the incubation
was continued for another 30 minutes at 45°C. The cell
suspension was then subjected to four freeze/thaw cycles
(30 minutes at −80°C/30 minutes at 45°C). The lysate was
then partially clarified by centrifugation at 18,500 × g for
10 minutes at 20°C. The supernatant was laid on top of an
iodixanol step gradient and centrifuged at 350,000 × g for
1 hour at 18°C. The interface between the 40% and 54%
iodixanol layers was withdrawn and spin-purified and concentrated using four washes with PBS in an Amicon
Ultra-15 100,000 MWCO spin concentrator (Thermo
Fisher, Rockford, IL)). The virus preparation was then
titered using real-time PCR with primers directed against
the cytomegalovirus (CMV) promoter region of the DNA
encapsulated in the virions.
Bilateral intracranial injection

On the day of surgery, mice were anesthetized with isoflurane and placed into a stereotaxic apparatus (51733D
digital dual manipulator mouse stereotaxic frame; Stoelting
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Co., Wood Dale, IL, USA). A midsaggital incision was used
to expose the skull. Using a dental drill mounted on the
stereotaxic frame, a total of four burr holes were made,
one hole for each frontal cortex and hippocampus. The following coordinates were used from bregma: frontal cortex,
anteroposterior, +2.0 mm, lateral ± 2.0 mm; hippocampus,
anteroposterior −2.7 mm, lateral ± 2.5 mm. These have
been previously established by the laboratory using dye
injections to confirm appropriate placement. A 26 gauge
needle attached to a 10 μL Hamilton syringe (Hamilton,
Reno, NV, USA) containing the AAV at a concentration of
2 × 109 genomes/μL to be injected was lowered 3.0 mm
ventral to bregma, and a 2 μL injection was made over a
4-minute period. The incision was cleaned and sutured.
Sutures were removed 2 weeks after surgery. The virus was
injected at the maximum titer possible based on the concentration supplied so as to achieve the greatest expression
of IFNγ.
Tissue processing

After injection with a lethal dose of Beuthanasia-D, mice
were perfused intracardially with 25 mL normal saline.
Brains were removed rapidly and bisected in the midsaggital plane. The left side of the brain was immersion
fixed in 4% paraformaldehyde. The right side was dissected with the frontal cortex and hippocampus being
isolated and flash frozen in liquid nitrogen and then
stored at −80°C. The left hemibrain was passed through
a series of 10, 20 and 30% sucrose solutions for cryprotection. Using a sliding microtome, 25 μm frozen
horizontal sections were collected and stored free floating in 1XDPBS containing sodium azide at 4°C.
Immunohistochemistry

Six floating sections spaced 300 μm apart spanning the
injection site (1800 to 3600 μm ventral to bregma) were
immunostained by using commercially available antibodies
against Aβ (Rabbit polyclonal Aβ1-16, Life Technologies,
Carlsbad, CA, USA), CD11b (Rat monoclonal, AbD Serotec,
Raleigh, NC, USA), and glial-fibrillary acidic protein
(GFAP; Rabbit polyclonal, Dako, Denmark). Immunohistochemistry was performed as previously described [21].
Briefly, sections were quenched for endogenous peroxidase, blocked and permeabalized. They were then incubated overnight in primary antibody at 4°C (Aβ 1:3000,
CD11b 1:3000, GFAP 1:10000). After washing, sections
were incubated for 2 hours in the appropriate biotinylated
secondary antibody (goat anti-rabbit IgG for Aβ and
GFAP, goat anti-rat for CD11b, all 1:3000; Vector Laboratories, Burlingame, CA, USA). Sections were then washed
and incubated for 1 hour in ABC. For CD11b and GFAP,
color development was performed using the DAB substrate kit with Nickel (Vector Laboratories). For Aβ, color
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development was performed using powder DAB (Sigma,
St Louis, MO, USA).
Stained sections were mounted, air dried overnight,
dehydrated and coverslipped in DPX (Electron Microscopy Sciences, Hatfield, PA, USA). Immunohistochemical analysis was performed by measuring percent area
occupied by positive stain using the Nikon Elements BR
image analysis system (Melville, NY, USA) as described
previously [22].

Quantitative real-time PCR

The Trizol plus RNA purification system (Life Technologies) was used to extract RNA from the frozen right
hippocampus according to the manufacturer’s instructions. RNA was quantified using the Biospec nano spectrophotometer (Shimaduz, Japan). cDNA was produced
using the cDNA High Capacity kit (Life Technologies)
according to the manufacturer’s instructions. Real-time
PCR was performed using the Fast TaqMan Gene Expression assay (Life Technologies). In each well of a
96-well plate, 0.5 μL cDNA (100 ng, based on the RNA
concentrations) was diluted with 6.5 μL RNase-free
water. One microliter of the appropriate gene probe
was added along with 10 μL of the Fast TaqMan to each
well. Target amplification was performed using ViiA7
(Applied Biosystems, Grand Island, NY, USA). The
thermal cycling conditions include a holding stage at
95°C followed by 40 cycles of denaturation at 95°C for
1 second and annealing/primer extension at 60°C for
20 seconds. All genes were normalized to 18S rRNA.
We determined the fold change for mice receiving
IFNγ-AAV compared with mice receiving GFP-AAV
using the –ΔΔCt method [23]. Table 1 shows the genes
tested along with their PMID and Taqman ID.

Table 1 Genes for real-time PCR
Gene of interest

PMID

Taqman ID

IL-6

NM_031168.1

Mm00446190_m1

IL-1β

NM_008361.3

Mm00434228_m1

IL-12a

NM_008351.2

Mm00434165_m1

IL-12b

NM_008352.2

Mm00434174_m1

ARG1

NM_007482.3

Mm00475988_m1

YM1 (Chil3)

NM_009892.2

Mm00657889_mH

CD86

NM_019388.3

Mm00444543_m1

FcγR1

NM_010186.5

Mm00438874_m1

FcγR3

NM_010188.5

Mm00438882_m1

TGFβ1

NM_011577.1

Mm01178820_m1

SPHK1

NM_011451.3

Mm01252544_m1

ARG, arginase; FcγR, Fc gamma receptor; IL, interleukin; SPHK, sphingosine
kinase; TGF, transforming growth factor.
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ELISA measurement

Protein for Aβ and IFNγ analysis was extracted from the
right frontal cortex in 1XDPBS with complete protease
and phosphatase inhibitor (Pierce Biotechnology Inc.,
Rockford, IL, USA). The samples were centrifuged at
10,000 × g at 4°C for 15 minutes. The supernatant was
removed and labeled the “soluble” extract. The pellet
was homogenized in 250 μL 70% formic acid and centrifuged at 10,000 × g at 4°C for 1 hour. The supernatant
was removed and neutralized 1:20 with 1 M Tris–HCl
and brought to a pH of 7 with HCl. This was labeled the
“insoluble” extract. Protein concentrations for the
soluble and insoluble extracts were determined using the
BCA protein assay kit (Pierce Biotechnology Inc.) according to the manufacturer’s instructions. The MesoScale Discovery multiplex ELISA system was used to
measure Aβ1-38, Aβ1-40, and Aβ1-42 levels in the
soluble and insoluble extracts (MSD, Gaithersburg, MD,
USA). The Meso-Scale Discovery Mouse Proinflammatory 7-Plex kit (MSD) was used to measure IFNγ levels
in the soluble extract. All steps were followed according
to the manufacturer’s directions except for the sample
incubation time which was left overnight.
Analysis

Data are presented as mean ± SEM. We used two-way
analysis of variance (ANOVA) based on the factors treatment (GFP-AAV or IFNγ-AAV injection) and survival
time (4 or 6 months) to evaluate main effects and treatment-by-time interaction within genotype (WT and APP/
PS1). No statistical comparisons were made across genotype. Because treatment effects at each time point were of
interest a priori, data are presented by treatment and time
point whether or not the treatment-by-time interaction is
significant.
Due to a high proportion of zero values, we used nonparametric two-way ANOVA on ranks to evaluate distributional differences in ELISA-determined IFNγ protein
levels. Similarly, we used two-way ANOVA on ranks to
evaluate differences in gene expression (measured by fold
change from GFP) as these data did not meet parametric
ANOVA assumptions. Ranks were assigned using the
RANK procedure, and ANOVA was performed using the
GLM procedure in SAS/STAT 9.3® (SAS, Cary, NC, USA).
Statistical significance was set at P < 0.05.

Results
To determine that the IFNγ-AAV resulted in expression
of IFNγ we performed an ELISA measurement. Measurement of IFNγ in the protein extracted from the right
frontal cortex showed a significant treatment effect such
that mice injected with IFNγ-AAV had a 5,000-fold increase in IFNγ levels at 4 and 6 months in both WT and
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APP/PS1 mice compared to mice receiving GFP-AAV
(Figure 1).
To determine the neuroinflammatory phenotype, right
hippocampal RNA was isolated and real time PCR was
performed for several genes specific to an M1, M2a, M2b
or M2c macrophage phenotype. Data are shown as fold
change compared to GFP-AAV at each time point for each
genotype. The GFP-AAV mice showed no significant
change in neuroinflammation over time (data not shown).
Overall, both WT and APP/PS1 mice responded to the
IFNγ-AAV with a robust M1 response. IL-12b was
increased in IFNγ-AAV treated mice at 4 and 6 months in
both genotypes, and IL-1β was increased at all time
points, except 6 months in WT (Figure 2A-D). Additionally, IL-6 and IL-12a showed significant increases at the
6-month (but not 4-month) time point in both WT and
APP/PS1 mice (Figure 2B,D). At the 6-month time point,
but not at the 4-month time point, M2a gene YM1
was significantly increased in WT and APP/PS1 mice
(Figure 2A-D). Also of note are increased M2b markers
CD86, FcγR1 and FcγR3 at the 4 and 6-month time point
(Figure 2B,D). Table 2 shows the fold-change values for
GFP-AAV- and IFNγ-AAV-treated mice. Interestingly,
while it may appear that the APP/PS1 mice are less
responsive to the IFNγ-AAV, it is actually due to the fact
that APP/PS1 mice normally have an inflammatory
response to the amyloid deposits in the brain and so the
fold-change achieved by the IFNγ-AAV is less than
in WT.
Next, assessment of CD11b immunohistochemistry in
the frontal cortex (images not shown) and the hippocampus (dentate gyrus shown, Figure 3A-H) was performed to
determine the effect of IFNγ on microglia. In all four brain
regions measured, for both WT and APP/PS1 mice

Figure 1 Protein analysis confirms IFNγ overexpression by
adeno-associated virus. **P < 0.01 for IFNγ-AAV compared to GFP-AAV
at that time point and genotype. AAV, adeno-associated virus; IFN,
interferon; GFP, green fluorescent protein; WT, wild-type.
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Figure 2 IFNγ induces an M1 neuroinflammatory phenotype. Relative gene expression for genes representative of the M1, M2a, M2b, and
M2c phenotypes. Data are shown as fold-change relative to mice receiving GFP-AAV at the given time point and genotype. (A) Wild-type (WT)
mice receiving IFNγ-AAV for 4 months (4 m). (B) WT mice receiving IFNγ-AAV for 6 months (6 m). (C) APP/PS1 receiving IFNγ-AAV for 4 months.
(D) APP/PS1 receiving IFNγ-AAV for 6 months. *P < 0.05, **P < 0.01, IFNγ-AAV compared to GFP-AAV of that time point and genotype. #P < 0.05,
##P < 0.01, 4-month IFNγ-AAV compared to 6-month IFNγ-AAV of that genotype. AAV, adeno-associated virus; AARG1, arginase 1; FCGR, Fc gamma
receptor; GFP, green fluorescent protein; IFN, interferon; IL, interleukin; SPHK1, sphingosine kinase 1; TGFB, transforming growth factor beta.

Table 2 Fold change values for real time PCR
GFP-AAV

IFNγ-AAV

WT

APP/PS1

WT

APP/PS1

Gene

4 mo

6 mo

4 mo

6 mo

4 mo

6 mo

4 mo

6 mo

IL-6

1.5 ± 0.51

1.4 ± 0.45

2.46 ± 1.36

1.16 ± 0.21

5.27 ± 2.8

92.42 ± 81.72

12.23 ± 7.43

15.03 ± 5.81

IL-1β

1.7 ± 0.72

1.2 ± 0.27

1.42 ± 0.57

1.15 ± 0.23

26.55 ± 8.8

3673.4 ± 3599.1

77.75 ± 31.53

96.07 ± 25.74

IL-12a

1.62 ± 0.68

1.25 ± 0.38

1.75 ± 0.79

1.4 ± 0.44

3.62 ± 1.9

29.53 ± 0.43

5.37 ± 3.92

89.85 ± 60.30

IL-12b

1.37 ± 0.94

1.29 ± 0.39

1.14 ± 0.43

1.68 ± 0.76

108.96 ± 36.47

109.55 ± 79.82

128.58 ± 103.11

239.43 ± 77.25

ARG1

1.95 ± 0.79

1.19 ± 0.34

1.41 ± 0.45

1.88 ± 0.75

0.55 ± 0.09

1.68 ± 0.30

0.49 ± 0.12

2.02 ± 0.36

YM1

1.87 ± 1.06

1.08 ± 0.19

1.31 ± 0.51

2.35 ± 1.17

2.91 ± 1.12

184.47 ± 174.22

6.48 ± 4.07

68.66 ± 23.88

CD86

1.21 ± 0.3

1.56 ± 0.66

1.09 ± 0.22

1.3 ± 0.93

21.2 ± 4.97

24.9 ± 4.51

66.85 ± 43.23

19.93 ± 7.52

FcγR1

1.2 ± 0.28

1.10 ± 0.24

1.12 ± 0.26

1.36 ± 0.55

13.45 ± 3.05

59 ± 34.83

9.11 ± 2.61

18.44 ± 2.65

FcγR3

1.49 ± 0.46

1.05 ± 0.15

1.14 ± 0.31

1.27 ± 0.44

4.9 ± 0.83

36.28 ± 10.41

4.89 ± 1.61

13.64 ± 1.17

TGFβ1

1.45 ± 0.61

1.29 ± 0.40

1.07 ± 0.19

1.23 ± 0.26

1.58 ± 0.33

3.53 ± 0.83

1.95 ± 0.28

1.95 ± 0.74

SPHK1

2.01 ± 1.28

1.07 ± 0.18

1.46 ± 0.60

1.58 ± 0.77

0.06 ± 0.02

8.23 ± 2.69

0.19 ± 0.03

2.21 ± 0.28

Bold font indicates P < 0.05 compared to GFP-AAV of that time point and genotype. AAV, adeno-associated virus; ARG1, arginase 1; FcγR, Fc gamma receptor;
GFP, green fluorescent protein; IFN, interferon; IL, interleukin; mo, months; SPHK1, sphingosine kinase 1; TGF, transforming growth factor; WT, wild-type.
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Figure 3 IFNγ causes an increase in CD11b staining. (A-D) Dentate gyrus of wild-type (WT) mice receiving GFP-AAV or IFNγ-AAV. (E-H) Dentate
gyrus of APP/PS1 mice receiving GFP-AAV or IFNγ-AAV. (I) Quantification of CD11b in the frontal cortex, CA1, CA3, and DG. **P < 0.01, IFNγ-AAV
compared to GFP-AAV at that time point and genotype. #P < 0.05, ##P < 0.01, 4-month IFNγ-AAV compared to 6-month IFNγ-AAV of that genotype.
Scale bar in A is for A-H and is equal to 50 μm. AAV, adeno-associated virus; DG, dentate gyrus, GFP, green fluorescent protein; IFN, interferon.

receiving IFNγ-AAV, there were statistically significant increases in CD11b staining, as measured by percent area
occupied by positive immunostain, at 6 months compared
to 4 months that were not observed in mice receiving
GFP-AAV (that is, the treatment-by-time interaction is
significant). In the frontal cortex, there was a statistically
significant increase in microglial staining at 6 months but
not 4 months in both WT and APP/PS1 mice injected
with IFNγ-AAV compared to mice receiving GFP-AAV
(Figure 3I). At 6 months in WT mice, there were significant increases in staining in the CA1, CA3 and (DG) regions (Figure 3A-D,I). APP/PS1 mice receiving IFNγ-AAV

only showed modest, non-significant increases at 4 months
(Figure 3E,F,I) but significant increases were observed in
all hippocampal regions by 6 months (Figure 3G,H,I).
Evaluation of astrogliosis using GFAP immunohistochemistry was also performed on the frontal cortex
(images not shown) and the hippocampus (dentate gyrus
shown, Figure 4A-H). Distribution of GFAP staining in
WT (Figure 4A,C) and APP/PS1 mice (Figure 4E,G) receiving GFP-AAV was typical for age and genotype [24].
Curiously, IFNγ-AAV injection in both the WT and APP/
PS1 mice resulted in decreased GFAP-positive staining.
We found significantly decreased GFAP staining 4 months
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Figure 4 IFNγ causes a decrease in GFAP staining. (A-D) Dentate gyrus of wild-type (WT) mice receiving GFP-AAV or IFNγ-AAV. (E-H) Hippocampus
of APP/PS1 mice receiving GFP-AAV or IFNγ-AAV. (I) Quantification of GFAP in the frontal cortex, CA1, CA3, and DG. *P < 0.05, **P < 0.01, IFNγ-AAV
compared to GFP-AAV at that time point and genotype. Scale bar in A is for A-H and is equal to 50 μm. AAV, adeno-associated virus; DG, dentate gyrus;
GFAP, glial fibrillary acidic protein; GFP, green fluorescent protein; IFN, interferon.

after IFNγ-AAV injection in the CA1, CA3, and DG regions of WT mice (Figure 4A,B,I) There were no significant changes in GFAP staining in the CA1, CA3, or DG
regions in the APP/PS1 mice at 4 months (Figure 4E,F,I).
At 6 months, there was a significant decrease in astrocyte
staining in the CA1, CA3 and DG regions in WT
(Figure 4C,D,I) and in the DG in APP/PS1 mice
(Figure 4G,H,I).
Finally, we examined the effect of IFNγ-AAV on Aβ
levels in the APP/PS1 mice. Aβ levels were determined by
immunohistochemistry and ELISA analysis. Aβ deposition
in the GFP-AAV mice showed a typical distribution of

APP/PS1 mice at this age both 4 and 6 months postinjection (Figure 5A,C). Immunohistochemical analysis of
the frontal cortex (images not shown) and the hippocampus (DG shown, Figure 5A-D) shows no significant change in Aβ deposition 4 months post-injection
(Figure 5A,B,E) but, at 6 months post-injection, IFNγAAV resulted in increased Aβ deposition in the frontal
cortex, CA1 and CA3 regions versus GFP-AAV treated
mice. Aβ deposition was elevated significantly at 6 months
compared to levels at 4 months in mice receiving IFNγAAV in all areas except the DG, where the effect was
marginally significant (Figure 5B,D,E).
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Figure 5 IFNγ increases Aβ deposition. (A-D) Dentate gyrus of APP/PS1 mice receiving GFP-AAV or IFNγ-AAV. (E) Quantification of Aβ in the
frontal cortex, CA1, CA3, and DG. *P < 0.05, IFNγ-AAV compared to GFP-AAV at that time point and genotype. #P < 0.05, ##P < 0.01, 4-month
IFNγ-AAV compared to 6-month IFNγ-AAV of that genotype. Scale bar in A is for A-D and is equal to 50 μm. Aβ, amyloid-beta; AAV, adeno-associated
virus; DG, dentate gyrus; GFP, green fluorescent protein; IFN, interferon.

Biochemical detection of Aβ was performed on PBS soluble and insoluble (formic acid soluble) protein extracts
from the left anterior cerebral cortex. Aβ1-38, 1-40 and
1-42 were analyzed by multiplexed ELISA analysis (Table 3).
IFNγ-AAV injection significantly increased soluble Aβ1-40
and marginally increased Aβ1-42 levels at 4 months

relative to GFP-AAV injection in APP/PS1 mice (Table 3).
Soluble Aβ1-38, Aβ1-40 and Aβ1-42 levels significantly
increased from 4 to 6 months in both treatment groups at
the same rate (that is, the treatment-by-time interactions
were not significant), but treatment group differences at
6 months were not significant due to higher variability in
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Table 3 Soluble and insoluble amyloid-beta levels measured by ELISA
Soluble (pg/μg protein)

Insoluble (pg/μg protein)

AAV injection

Survival (months)

Aβ1-38

Aβ1-40

Aβ1-42

Aβ1-38

Aβ1-40

Aβ1-42

GFP-AAV

4

1.67 ± 0.77

2.97 ± 0.28

12.90 ± 2.24

9.04 ± 1.99

98.70 ± 36.77

903.27 ± 56.1

GFP-AAV

6

3.16 ± 0.75

5.10 ± 0.44

25.37 ± 3.81

23.82 ± 2.83

335.53 ± 64.95

1634.87 ± 397.9

IFNγ-AAV

4

3.68 ± 0.23

5.41 ± 0.91

27.17 ± 4.94

20.56 ± 8.48

295.78 ± 87.63

2855.26 ± 1267.9

IFNγ-AAV

6

4.95 ± 0.51

6.57 ± 0.89

38.90 ± 7.35

27.10 ± 4.10

269.72 ± 55.2

2047.32 ± 436.0

Bold indicates P < 0.05 compared to GFP-AAV at the same time point. Aβ, amyloid-beta; AAV, adeno-associated virus; ELISA, enzyme-linked immunosorbent assay;
IFN, interferon.

the IFNγ-AAV treated mice. Main effects for treatment
were significant for soluble Aβ1-38, Aβ1-40 and Aβ1-42.
No significant changes due to treatment or time were observed for insoluble Aβ, with the exception of Aβ1-38,
where there was a main effect due to time (P = 0.024).

Discussion
Alzheimer’s disease, while characterized by amyloid
plaques and neurofibrillary tangles, is associated with a robust neuroinflammatory response. Using the macrophage
classification system of M1, M2a, M2b and M2c [6,7] we
recently showed that the neuroinflammatory state is highly
variable in the early stages of AD [25]. This variability was
apparent in a population that was clinically and pathologically indistinguishable suggesting that neuroinflammation may be a source of variability in the Alzheimer’s
population. Furthermore, we hypothesize the neuroinflammatory state will influence progression of the disease and
also response to therapeutic interventions. To better determine the role these distinct neuroinflammatory phenotypes have on amyloid pathology, we developed AAV
vectors to express IFNγ, the initiator of an M1 neuroinflammatory state [26,27], with the goal of chronically polarizing the state of the brain to an M1 state. We then
injected this into the brains of APP/PS1 mice and examined their pathological progression 4 and 6 months postinjection. Overall, our data suggest that, while initially we
did polarize the phenotype to M1, by 6 months the neuroinflammatory phenotype showed a combination of M1
and M2. Amyloid deposition was unaffected by the M1
phenotype but increased when the combination of inflammatory markers were increased. Whether this increase in
Aβ is due to the M2 phenotypes direct actions or indirect
actions on the M1 microglia remains unclear.
Macrophage activation can be categorized as M1, M2a,
M2b and M2c. M1 is characterized by high IL-12 and low
IL-10 while the M2 phenotypes are characterized by high
IL-10 and low IL-12 [8]. Additionally, M1 macrophages
express high levels of IL-1β, TNFα and IL-6 [6]. M2a macrophages are associated with wound healing and repair
gene expression including YM1 and ARG1 [8]. The M2b
phenotype is very much like an M1 phenotype with the

exception of the IL-10/IL-12 balance and high expression
of CD86 [8]. Finally, the M2c state is characterized by high
transforming growth factor beta and sphingosine kinase 1
[6,9]. IFNγ, with and without LPS or TNFα, is the typical
M1 phenotype stimulus [26,27]. Using BV2 microglial cell
cultures, we have previously shown that treatment of BV2
cells with IFNγ results in an M1 phenotype [28]. We hypothesized that a continuous presence of IFNγ would
chronically polarize the inflammatory state of the brain to
an M1 state. We found that expression of IFNγ through
intracranial injection of IFNγ-AAV successfully induced
an M1 phenotype at 4 months post-injection, but over
time this transitioned to a combined M1 and M2 phenotype by 6 months. Both the early M1 phenotype and the
6 month transition to a mixed phenotype were present in
both WT and APP/PS1 mice, indicating that the APP/PS1
mice and WT mice responded similarly to the IFNγ-AAV
injection.
CD11b (CR3) has been used as one of a handful of
microglial activation markers. In the mouse, CD11b labels
ramified resting microglia, while GFAP labels astrocytes
and the intensity of the staining is generally increased with
inflammatory stimuli [29,30]. There is an assumption in
the field that microglial activation and astrogliosis correspond to high levels of pro-inflammatory cytokines such as
IL-1β and IL-6. In the current study, we find that CD11b
immunostaining is not affected by the IFNγ-AAV injection at the 4-month time point, when the neuroinflammatory state is primarily M1, but is only increased when M2
markers are also increased. We also find that GFAP staining decreases when M2 markers increase even though
M1 genes are still high. These data suggest that more
careful analysis of neuroinflammatory markers is necessary for appropriate interpretation of data. The CD11b
data here would indicate that inflammation is only increased at the 6-month time point, yet we see that at the
4-month time point IL-1β and IL-12 are significantly
elevated.
The role of neuroinflammation on amyloid deposition remains controversial. Studies with LPS injection have shown
both decreases and increases in amyloid load with neuroinflammation [15,17,31]. Additionally, microglial “activation”
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has been linked to both increased and decreased amyloid
loads [29,31]. Our goal in this study was to determine the
influence of an M1 neuroinflammatory phenotype on
amyloid deposition. At the 4-month time-point, when M1
neuroinflammation predominates in the brains of mice
injected with IFNγ-AAV, amyloid deposition appears unaffected with no significant difference between IFNγ-AAV
and GFP-AAV injected mice. We do find increased Aβ
deposition at the 6-month time point, but this is in the
presence of a mixed neuroinflammatory phenotype. At
this time point we see not only M1 markers including
IL-12, IL-1β and IL-6, but also the M2a marker YM1. This
is not the first time that M1 markers have been associated
with unchanging or decreased amyloid deposition [13].
Indeed, anti-Aβ immunotherapy initiates activation of M1
markers [32]. Furthermore, we have previously shown that
lithium treatment results in unchanging biochemical
levels of Aβ but increased amyloid deposition accompanied by increased expression of M2a markers YM1, ARG1
and IL-1 receptor antagonist [22]. In this study we also
see relatively unchanging biochemical levels of Aβ,
increased Aβ deposition shown by an increase in Aβ staining and an increase in the expression of M2a markers at
6 months. This increase in Aβ staining at 6 months
implies that a mixed neuroinflammatory phenotype increases amyloid burden. While the mechanism is unclear,
it appears that an M2a phenotype promotes amyloid
deposition in the absence of changing total Aβ levels.
Future studies will attempt to elucidate the mechanism of
this phenomenon.
Human data from Alzheimer’s patients also shows a
similar trend in neuroinflammatory switching. Our laboratory has previously shown that, in early AD, patients are
polarized towards either an M1 or an M2a phenotype
[25]. By end-stage AD, patients have a combined M1, M2a
and M2c phenotype. Also, early AD patients who polarized towards an M2a phenotype had an increased neuritic plaque load compared to those polarized towards an
M1 phenotype. This suggests that the transition to a
mixed phenotype is associated with disease progression
and increased amyloid burden. Future studies on the
effects of the neuroinflammatory phenotypes, especially
an M2 phenotype, could provide possible therapeutic
targets for AD progression and potential biomarkers to
determine the stage of AD.

Conclusions
Expression of IFNγ through AAV successfully induced an
M1 phenotype at 4 months that transitioned to a mixed
phenotype by 6 months. This transition also appeared
with an increase in amyloid burden suggesting that a
mixed phenotype, or enhanced expression of M2a and
M2c markers, could contribute to increasing amyloid
burden and disease progression.
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